Sugi Predict

Sugi Predict / Compounds / SCHEMBL2534005

SCHEMBL2534005

SCHEMBL2534005

O=Cc1c[nH]c2c(F)cc(F)cc12

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GPR84 Q9NQS5 1/20 0.53
▸ PIM3 Q86V86 8/20 0.45
▸ PIM1 P11309 6/20 0.45
▸ ERN1 O75460 1/20 0.44
▸ TRIM24 O15164 1/20 0.42
▸ TRIM33 Q9UPN9 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.40
▸ LMNA P02545 1/20 0.40
▸ AR P10275 1/20 0.39
▸ CYP2A6 P11509 2/20 0.39
▸ IMPDH2 P12268 1/20 0.39
▸ PIM2 Q9P1W9 1/20 0.38
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29952475 0.84 ERN1 (0.43) GPR84PIM3PIM1ERN1TRIM24
SCHEMBL29953212 0.82 PIM3 (0.49) GPR84PIM3PIM1ERN1TRIM24
SCHEMBL29952505 0.82 TRIM24 (0.40) GPR84PIM3PIM1ERN1TRIM24
SCHEMBL21624143 0.82 PIM3 (0.44) GPR84PIM3PIM1ERN1TRIM24
SCHEMBL29956575 0.82 AR (0.42) GPR84PIM3PIM1ERN1TRIM24
SCHEMBL29953877 0.82 AR (0.43) GPR84PIM3PIM1ERN1TRIM24
SCHEMBL671315 0.82 TRIM24 (0.56) GPR84PIM3PIM1ERN1TRIM24
SCHEMBL21356468 0.82 HTR1A (0.40) GPR84PIM3PIM1ERN1TRIM24
SCHEMBL25350152 0.78 TRIM24 (0.37) GPR84PIM3PIM1ERN1TRIM24
SCHEMBL1420304 0.78 TRIM24 (0.37) GPR84PIM3PIM1ERN1TRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4710923-A2 INDOLE AHR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2026-03-18 — — EP disclosed
EP-3612030-B1 INDOLE AHR INHIBITORS AND USES THEREOF IKENA ONCOLOGY INC (US) 2025-12-24 — — EP disclosed
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12077542-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-09-03 — — US disclosed
CN-110831600-B Indole AHR inhibitors and uses thereof 医肯纳肿瘤学公司 2023-10-17 — — CN disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2018-11-15 — — US disclosed
WO-2018195397-A2 INDOLE AHR INHIBITORS AND USES THEREOF KYN THERAPEUTICS (US) 2018-10-25 — — WO disclosed
EP-1859798-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2015-12-30 — — EP disclosed
US-8044090-B2 N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor ELI LILLY (US) 2011-10-25 — — US disclosed
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2009-12-10 — — US disclosed
EP-1859798-A1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2007-11-28 — — EP disclosed
EP-1379239-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2007-09-12 — — EP disclosed
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2007-05-03 — — US disclosed
US-7157488-B2 N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor ELI LILLY AND COMPANY (US) 2007-01-02 — — US disclosed
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 GPR84 100/4885PIM3 1399/4885PIM1 1683/4885
US-11358969-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 GPR84 100/4885PIM3 1399/4885PIM1 1683/4885
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 GPR84 100/4885PIM3 1399/4885PIM1 1683/4885
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B GPR84 125/4885PIM3 4679/4885PIM1 4832/4885
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B GPR84 125/4885PIM3 4679/4885PIM1 4832/4885
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 GPR84 100/4885PIM3 1399/4885PIM1 1683/4885
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B GPR84 125/4885PIM3 4679/4885PIM1 4832/4885
US-12077542-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 GPR84 100/4885PIM3 1399/4885PIM1 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.